April 25, 2006 -- Millipore will buy fellow lab tools developer Seriologicals for a total of $1.4 billion, including debt; DOV Pharma said its analgesic for back pain failed its Phase III trial; Surfaxin from Discovery Labs has not achieved its stability parameters, delaying approval; according to Cephalon, the FDA will take an additional three months to decide the fate of Sparlon, the potential therapy for ADHD; Amgen agreed to develop compounds that treat eye diseases for Alcon; Abraxis BioScience bought a Puerto Rican manufacturing facility from Pfizer; ViaCell collaborated with Pall, making it possible to collect umbilical cord blood after a Caesarean section; NeoPharm announced additional results for its brain cancer drug; NeoRx extended its Phase II trial of picoplatin for small-cell lung cancer into Eastern Europe; Peregrine Pharma received a $406,000 Department of Defense grant to study its cancer drug; and EntreMed will enter its breast cancer drug in a Phase Ib study as an adjunct to paclitaxel. The Centient Biotech 200™ was 37 points lower at 3758.74, a drop of .98%. More details...
